The risk of diabetes mellitus in patients with post-ERCP pancreatitis—A preliminary report - 24/11/22
Doi : 10.1016/j.clinre.2022.102027
Halim Francis a, Perveen Aslam b, Timothy Greenaway a, c, Andrew Thomson a, b, ⁎ 
a The Australian National University Medical School, Canberra, Australia
b Gastroenterology Unit, The Canberra Hospital, Canberra, Australia
c Endocrinology Unit, The Canberra Hospital, Canberra, Australia
⁎Address for correspondence: Gastroenterology Unit, The Canberra Hospital, PO Box 11, Woden, Canberra, 2606, AustraliaGastroenterology UnitThe Canberra HospitalPO Box 11, WodenCanberra2606Australia
Highlights |
• | What is already known about this subject? |
• | There is evidence from cohort studies that all cause pancreatitis is associated with the development of diabetes but data specifically related to ERCP related pancreatitis are lacking. |
• | ERCP is a common cause of pancreatitis, occurring in at least 2500 patients each year in France alone and a similar proportion of the population of other countries. |
• | What are the new findings? |
• | After a maximal follow up of only 10.5 years, almost one fifth of a cohort of post ERCP pancreatitis developed diabetes, which is significantly higher than the expected incidence. |
• | How might it impact on clinical practice in the foreseeable future? |
• | Patients who develop post ERCP pancreatitis may benefit from careful monitoring for diabetes in the years following their ERCP. |
Keywords : Endoscopic retrograde cholangiopancreatography, Post-ERCP pancreatitis, Diabetes mellitus, Acute pancreatitis, Complications
© 2022
Pubblicato da Elsevier Masson SAS.
Vol 46 - N° 10
Articolo 102027- Dicembre 2022 Ritorno al numero
Articolo precedente
- COVID-19-associated secondary sclerosing cholangitis – A case series of 4 patients
- Filipa Bordalo Ferreira, Margarida Mourato, Sofia Bragança, Joana Batista Paulo, Rita Sismeiro, André Pereira, Ana Nassauer Mónica, Luís Carvalho Lourenço, Mariana Cardoso
- Drug induced hepatitis and SARS-CoV-2 vaccination: Correspondence
- Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?